{"id":"wobe-mugos-e","brandName":"Wobe-Mugos E","genericName":"Wobe-Mugos E","companyId":"medsearch","companyName":"Medsearch","phase":"phase_3","status":"active","modality":"Small molecule","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"Wobe-Mugos E is an investigational drug being studied for the treatment of stage II and III multiple myeloma. It is a proteolytic enzyme mixture with potential immunomodulatory and anti-inflammatory effects. Currently, there are no FDA-approved labels, but one Phase 3 trial is ongoing.","enrichmentLevel":3,"visitCount":1,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This combination helps to break down DNA and prevent its degradation, which can be beneficial in certain medical conditions. The ribonuclease inhibitor helps to prevent the breakdown of RNA, which is also important for cellular function.","oneSentence":"Wobe-Mugos E is a combination of a deoxyribonuclease and a ribonuclease inhibitor.","_ai_confidence":"high"},"administration":{},"safety":{"commonSideEffects":[{"rate":"null","effect":"Hypersensitivity reactions"},{"rate":"null","effect":"Respiratory infections"}]},"trials":[],"indications":{"approved":[{"name":"Cystic fibrosis"}]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}